Immutep Reports Positive Phase I Progress for First-in-Class Autoimmune Drug IMP761

Immutep Ltd ( (AU:IMM) ) has provided an announcement.

Immutep reported positive progress from its first-in-human Phase I trial of IMP761, a first-in-class LAG-3 agonist antibody designed to suppress pathogenic T cell responses in autoimmune diseases. The single ascending dose part of the study has been completed with dosing up to 14 mg/kg, showing IMP761 was well tolerated with no dose-limiting toxicities.

The trial is now in the multiple ascending dose phase, with completion expected in the third quarter of 2026, and detailed data to be presented at the EULAR congress in June 2026. The results support IMP761’s potential as a targeted immunosuppressive therapy that addresses the root cause of autoimmune diseases, reinforcing Immutep’s strategic position in developing differentiated treatments for multi-billion-dollar autoimmune markets.

The most recent analyst rating on (AU:IMM) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.

More about Immutep Ltd

Immutep Limited is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a pioneer in therapeutics targeting Lymphocyte Activation Gene-3 (LAG-3), leveraging this immune checkpoint to either stimulate or suppress immune responses across large, underserved markets.

Average Trading Volume: 16,965,718

Technical Sentiment Signal: Sell

Current Market Cap: A$75.16M

For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.